ASCO 2021 | HRQoL outcomes in the APOLLO trial
Evangelos Terpos, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, talks on patient reported health-related quality of life (HRQoL) outcomes in the APOLLO trial (NCT03180736). The Phase III APOLLO trial is investigating pomalidomide and dexamethasone with or without subcutaneous daratumumab in patients with relapsed/refractory (R/R) multiple myeloma. Prof. Terpos reports that no changes in HRQoL were reported with the addition of daratumumab to lenalidomide and dexamethasone, as well as a notable reduction in pain in favor of the addition of daratumumab. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Evangelos Terpos, MD, PhD, has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Genesis Pharmaceuticals, Janssen-Cilag, Novartis, Sanofi and Takeda; has participated in a consulting or advisory role for Amgen, Celgene, Genesis Pharmaceuticals, Janssen-Cilag, Sanofi and Takeda; has received research funding from Amgen, Genesis Pharmaceuticals, Janssen-Cilag, Sanofi and Takeda, and has received travel, accommodation or expenses from Amgen, Genesis Pharmaceuticals, Janssen-Cilag and Takeda.
